secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-067509
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Artiva Biotherapeutics appoints Thad Huston as CFO effective Feb 18, 2026
-------------------------------------------------------------------------

- Thad Huston appointed CFO, principal financial and accounting officer, effective Feb 18, 2026.
- Salary $540,000; discretionary annual cash bonus target of 40% of base salary.
- Inducement award of 220,000 RSUs vesting 25% Feb 15, 2027, then quarterly over three years.
- Severance: 9 months base salary (non-CIC) or 12 months + full target bonus (CIC), plus COBRA and accelerated vesting.
- Huston previously CFO/COO at Galapagos NV and held senior roles at Kite Pharma, LivaNova, and Johnson & Johnson.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526067509/0001193125-26-067509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526067509/artv-20250128.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-067509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer